GSKGLAXF +4.77%69 EV-to-EBITDA is 9.19 as of Jul. 07, 2026, which is 11% below its 10-year median of 10.33. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.82 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 741 Drug Manufacturers companies, GSK ranks better than 68.02% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, GSK's enterprise value is $129,898 Mil.
GSK's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $14,128 Mil. Therefore, GSK's EV-to-EBITDA for today is 9.19.
The historical rank and industry rank for GSK's EV-to-EBITDA or its related term are showing as below:
GLAXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.27 Med: 10.33 Max: 29.44
Current: 9.19
During the past 13 years, the highest EV-to-EBITDA of GSK was 29.44. The lowest was 7.27. And the median was 10.33.
GLAXF's EV-to-EBITDA is ranked better than 68.02% of 741
companies
in the Drug Manufacturers industry
Industry Median: 12.86
vs GLAXF: 9.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-07), GSK's stock price is $27.00.
GSK's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.917. Therefore, GSK's PE Ratio (TTM) for today is 14.08.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
GSK (OTCPK:GLAXF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GSK's share price for today is $27.00.
GSK's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.917.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for GSK's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, GSK's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GSK's EV-to-EBITDA falls into.
GSK's current Enterprise Value is $129,898 Mil.
GSK's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,128 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (GLAXF) has a EV-to-EBITDA of 9.19 as of Jul. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GSK. This is 11% below median its historical median of 10.33. Over the past decade, GSK's EV-to-EBITDA has ranged from 7.27 to 29.44. According to the industry distribution chart, GSK ranks #237 out of 741 companies in the Drug Manufacturers industry, placing it in the top 32%.
Is GSK's EV-to-EBITDA too high?
GSK's current EV-to-EBITDA of 9.19 is 11% below median its 10-year median of 10.33. Over the past 10 years, this metric has ranged from a low of 7.27 to a high of 29.44. The Drug Manufacturers industry median EV-to-EBITDA is 12.86. GSK's value of 9.19 is 28.5% below this industry median. Based on the distribution chart, GSK ranks #237 out of 741 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #237 out of 741 companies for EV-to-EBITDA. This puts GSK in the upper half of its industry. The industry median EV-to-EBITDA is 12.86. GSK's value of 9.19 is 28.5% below this benchmark. Historically, GSK's own EV-to-EBITDA has ranged from 7.27 to 29.44 over the past decade. While the company's 10-year median is 10.33 vs. the industry median of 12.86, GSK has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.86, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current EV-to-EBITDA of 9.19 is 28.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GSK. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current EV-to-EBITDA is 9.19, which is 11% below median its own 10-year median of 10.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.82, compared to a current price of $27.00 — trading 23.7% above its estimated fair value. The current EV-to-EBITDA is 9.19, which is 11% below median its 10-year median of 10.33 and 28.5% below the Drug Manufacturers industry median of 12.86. GSK's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For GSK (GLAXF), the current EV-to-EBITDA is 9.19 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $27.00 is trading 23.7% above its estimated GF Value™ of $21.82.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
EV-to-EBITDA: 9.19 (11% below median its 10-year median of 10.33)
GF Value™: $21.82 vs. price of $27.00 (23.7% above fair value)
Industry Position: 28.5% below the Drug Manufacturers median (#237 of 741)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score
Get the complete analysis for GLAXF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
